InMode (INMD) to Release Quarterly Earnings on Thursday

InMode (NASDAQ:INMD) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.40 per share for the quarter. InMode has set its FY24 guidance at $2.53-2.57 EPS.Investors that wish to register for the company’s conference call can do so using this link.

InMode (NASDAQ:INMD) last issued its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. The firm had revenue of $126.80 million for the quarter, compared to the consensus estimate of $124.77 million. InMode had a net margin of 40.22% and a return on equity of 29.80%. InMode’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same period last year, the firm posted $0.69 EPS. On average, analysts expect InMode to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

InMode Stock Down 0.2 %

Shares of NASDAQ:INMD opened at $17.19 on Wednesday. The company has a market cap of $1.44 billion, a PE ratio of 7.47 and a beta of 2.16. The company’s 50-day moving average price is $20.13 and its 200 day moving average price is $21.43. InMode has a fifty-two week low of $16.82 and a fifty-two week high of $48.25.

Analyst Upgrades and Downgrades

INMD has been the topic of several recent research reports. Barclays cut their price objective on shares of InMode from $34.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, April 12th. Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Tuesday, April 9th. Finally, UBS Group boosted their price target on shares of InMode from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 14th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $32.80.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.